Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Sells $157,088.16 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the sale, the chief accounting officer now owns 19,241 shares of the company’s stock, valued at approximately $483,141.51. This trade represents a 24.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Travis Alvin Thompson also recently made the following trade(s):

• On Thursday, October 3rd, Travis Alvin Thompson sold 153 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $22.26, for a total transaction of $3,405.78.

Bicycle Therapeutics Stock Performance

Bicycle Therapeutics stock opened at $21.79 on Friday. The business’s 50-day simple moving average is $24.62 and its two-hundred day simple moving average is $23.16. The company has a market cap of $1.04 billion, a PE ratio of -6.62 and a beta of 0.89. Bicycle Therapeutics plc has a fifty-two week low of $13.07 and a fifty-two week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm’s revenue was down 50.0% on a year-over-year basis. During the same period in the prior year, the company earned ($1.26) earnings per share. As a group, analysts predict that Bicycle Therapeutics plc will post -3.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BCYC has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $55.00 price target on shares of Bicycle Therapeutics in a report on Friday, November 1st. Needham & Company LLC reissued a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. B. Riley downgraded shares of Bicycle Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $33.00 to $28.00 in a research report on Wednesday, August 7th. Finally, Stephens assumed coverage on Bicycle Therapeutics in a report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 target price for the company. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $40.13.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of institutional investors have recently added to or reduced their stakes in BCYC. Concurrent Investment Advisors LLC acquired a new position in shares of Bicycle Therapeutics during the 1st quarter worth about $543,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Bicycle Therapeutics by 12.8% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 883,105 shares of the company’s stock valued at $21,989,000 after acquiring an additional 100,107 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in shares of Bicycle Therapeutics by 13.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,038,917 shares of the company’s stock worth $25,869,000 after acquiring an additional 121,613 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Bicycle Therapeutics by 45.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 401,646 shares of the company’s stock valued at $10,001,000 after purchasing an additional 124,809 shares during the last quarter. Finally, Baker BROS. Advisors LP raised its stake in Bicycle Therapeutics by 176.1% in the 1st quarter. Baker BROS. Advisors LP now owns 4,942,823 shares of the company’s stock valued at $123,076,000 after purchasing an additional 3,152,433 shares during the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.